Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jan;65(1):122-132.
doi: 10.1007/s10384-020-00790-9. Epub 2021 Jan 20.

Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study

Osamu Mimura  1 , Hitoshi Ishikawa  2 , Takeshi Kezuka  3 , Keigo Shikishima  4 , Tone Suzuki  5 , Makoto Nakamura  6 , Hideki Chuman  7 , Kenji Inoue  8 , Akiko Kimura  9 , Akiko Yamagami  8 , Maki Mihoya  10 , Yuzo Nakao  11
Affiliations
Clinical Trial

Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study

Osamu Mimura et al. Jpn J Ophthalmol. 2021 Jan.

Abstract

Purpose: To evaluate the efficacy and safety of intravenous "freeze-dried sulfonated human normal immunoglobulin (GGS)" in patients with steroid-resistant optic neuritis (ON).

Study design: Multicenter, prospective, double-blind, parallel-group, randomized controlled trial.

Methods: Patients with steroid-resistant acute ON were randomly assigned to receive either intravenous GGS (GGS group) or intravenous methylprednisolone (steroid pulse [SP] group). Visual acuity (logarithm of the minimum angle of resolution [logMAR]), mean deviation (MD) value of the Humphrey Field Analyzer, and critical flicker fusion frequency were measured as efficacy endpoints; adverse events (AEs) were assessed as the safety endpoint.

Results: Thirty-two patients (16 patients/group) received the study drugs. The primary endpoint, change in logMAR at week 2 compared to baseline, showed no statistically significant intergroup difference. However, compared with the SP group, change in the GGS group was increasingly indicative of visual improvement, with least squares mean difference of > 0.3 logMAR. On post-hoc analyses, the percentage of patients in the GGS and SP groups with improvement by ≥ 0.3 logMAR at week 2 were 75.0% and 31.3%, respectively. Changes in MD values at week 2 compared to baseline were 9.258 ± 8.296 (mean ± standard deviation) dB and 3.175 ± 6.167 dB in the GGS and SP groups, respectively. These results showed statistically significant intergroup differences (visual acuity improvement, P = 0.032; change in MD values, P = 0.030). No clinically significant AEs were observed.

Conclusion: Our results suggest that intravenous immunoglobulin could be a safe and efficacious therapeutic option for prompt treatment of steroid-resistant acute ON.

Trial registration: JapicCTI-132080.

Keywords: Anti-aquaporin-4 antibody; Intravenous immunoglobulin; Optic neuritis; Phase III; Steroid-resistant.

PubMed Disclaimer

References

    1. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581–8. - DOI
    1. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773–5. - DOI
    1. Wakakura M, Mashimo K, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic neuritis treatment trial multicenter cooperative research group (ONMRG). Jpn J Ophthalmol. 1999;43:133–8. - DOI
    1. Kang H, Chen T, Li H, Xu Q, Cao S, Wei S. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol. 2017;264:2130–40. - DOI
    1. Kezuka T, Usui Y, Yamakawa N, Matsunaga Y, Matsuda R, Masuda M, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuro-ophthalmol. 2012;32:107–10. - DOI

Publication types

LinkOut - more resources